美国乔治城大学医学之星医院Metin Ozdemirli团队研究了cilta-cel CAR T细胞治疗后发生的无痛CD4+CAR T细胞淋巴瘤。该研究于2024年6月13日发表在《新英格兰医学杂志》上。

研究组在一名患者中诊断出涉及小肠的无痛CD4+细胞毒性嵌合抗原受体（CAR）T细胞淋巴瘤，该患者先前接受过cilta-cel CAR T细胞疗法治疗骨髓瘤。靶向信使核糖核酸测序显示肿瘤细胞中存在CAR基因产物。肿瘤和外周血样本的全基因组测序鉴定了SSU72基因第二内含子内的单个慢病毒插入位点。此外，在肿瘤样本中发现了许多可能导致恶性转化的基因改变。

附：英文原文

Title: Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

Author: Metin Ozdemirli, Thomas M. Loughney, Emre Deniz, Joeffrey J. Chahine, Maher Albitar, Stefania Pittaluga, Sam Sadigh, Philippe Armand, Aykut Uren, Kenneth C. Anderson

Issue&Volume: 2024-06-13

Abstract: Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene. In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.)

DOI: NJ202406133902211

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2401530